Day: June 3, 2022
Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will share an update on its allogeneic CAR T
Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Healthcare